Site specific screening for point mutations in ornithine transcarbamylase deficiency.
AUTOR(ES)
Feldmann, D
RESUMO
Ornithine transcarbamylase (OTC) deficiency is a frequent X linked disorder of the urea cycle which is responsible for lethal neonatal hyperammonaemia in males and for various clinical symptoms in heterozygous females. In order to improve the efficiency of our screening for mutant genotypes, we focused on molecular domains of functional or structural importance in the OTC gene, namely the carbamyl phosphate binding domain (encoded by the third exon) and the MspI restriction sites (CCGG) of the coding sequence (located in exons 2 and 7 respectively), as they contain mutation hot spots (CpG doublets). Using this procedure, we were able to identify three new mutant genotypes in OTC deficient children including one nonsense mutation (E 87 K, G 50 ter, G 162 R). Since genetic counselling for OTC deficiency is frequently difficult, molecular screening directed towards specific sites of the coding sequence could allow rapid detection of mutant genotypes and help solve diagnostic problems, especially when carrier status cannot be clarified easily.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1016021Documentos Relacionados
- Characterization of point mutations in the same arginine codon in three unrelated patients with ornithine transcarbamylase deficiency.
- In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.
- Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency
- A screening test for IgG deficiency.
- The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations.
